Cellectis (CLLS) Lowered to “Hold” at Zacks Investment Research
Cellectis (NASDAQ:CLLS) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research note issued to investors on Monday.
According to Zacks, “Cellectis SA is a gene-editing company. The company focused on developing immunotherapies based on gene edited engineered CAR-T cells. Cellectis SA is based in Paris, France. “
Other research analysts have also recently issued reports about the stock. ValuEngine upgraded shares of Cellectis from a “hold” rating to a “buy” rating in a report on Thursday, November 1st. BidaskClub raised shares of Cellectis from a “sell” rating to a “hold” rating in a research note on Saturday, October 6th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and three have issued a buy rating to the company. Cellectis currently has an average rating of “Hold” and an average target price of $48.00.
A number of large investors have recently added to or reduced their stakes in the stock. Macquarie Group Ltd. purchased a new stake in Cellectis in the third quarter worth about $5,390,000. Henry James International Management Inc. purchased a new stake in Cellectis in the third quarter worth about $1,003,000. Point72 Asset Management L.P. lifted its stake in Cellectis by 118.1% in the third quarter. Point72 Asset Management L.P. now owns 156,133 shares of the biotechnology company’s stock worth $4,406,000 after acquiring an additional 84,533 shares during the period. First Light Asset Management LLC purchased a new stake in Cellectis in the third quarter worth about $2,154,000. Finally, Opaleye Management Inc. purchased a new stake in Cellectis in the third quarter worth about $3,104,000. 27.36% of the stock is owned by institutional investors.
Cellectis SA, a clinical stage biotechnological company, develops and sells immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer in France. The company operates through two segments, Therapeutics and Plants. Its lead product candidate is UCART19, an allogeneic T-cell product candidate for the treatment of CD19 expressing hematologic malignancies, which develop in acute lymphoblastic leukemia (ALL).
Recommended Story: What is intrinsic value?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Cellectis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellectis and related companies with MarketBeat.com's FREE daily email newsletter.